OCT CHANGES IN MACULAR RETINAL THICKNESS DURING A-VEGF THERAPY
Keywords:
Abstract
Macular edema is the leading cause of vision loss in the increasingly frequent occurrence of diabetes mellitus, a true epidemic in developed countries. Diabetic macular edema is closely related to lifestyle, obesity, smoking or high blood pressure. Macular oedema is the leading cause of vision loss in people with diabetes in developed countries, and its prevalence is directly related to the duration of diabetes. Its incidence varies from publication to publication, ranging between 7.5% and 15.2%, and is more common in patients with type 2 diabetes receiving insulin.The significance of the incidence of diabetic macular oedema is directly related to the patient's metabolic control and the presence of risk factors, as we will see below.
Similar Articles
-
ASSESMENT OF YOUTH REPRODUCTIVE HEALTH SERVICE PREFERENCES, ARAB BORDADE HEALTH CENTER GUMBI BORDERED WOREDA WEST HARARGHE, OROMIA REGION, ETHIOPIA
The American Journal of Medical Sciences and Pharmaceutical Research: No. 05 (2022) / Jegnaw Zenebe Gizaw, Salah, Amanuel, -
Criteria For Evaluating Student Dental Health Index In Accordance With The «8020» Program Methodology
The American Journal of Medical Sciences and Pharmaceutical Research: No. 11 (2020) / Farrukh Aslidinovich Ismatov, Khasanova Lola Emilievna, -
National Processes In Uzbekistan And The Formation Of The Internationalist Maturity Of The Younger Generation
The American Journal of Medical Sciences and Pharmaceutical Research: No. 06 (2021) / Soatboy Yuldashev, Yusup Halimbetov, Marhabo Usmanova, Naimova Z.S, Khamraeva M, -
DANGERS OF DRUG ABUSE AMONG THE YOUTHS IN KEBBI STATE
The American Journal of Medical Sciences and Pharmaceutical Research: No. 07 (2023) / Abubakar Danjuma Bundaram , -
IMPACT OF COVID-19 ON THE PROFILE, SEASONALITY AND INCIDENCE OF FEMUR FRACTURE CASES IN BRAZILIAN YOUNG ADULTS
The American Journal of Medical Sciences and Pharmaceutical Research: No. 11 (2023) / Eduardo Romera Alves de Souza, Fábio Lucas Rodrigues, Matheus Marques Ferreira, Pedro Bernardi Soares de Camargo, Gabriel Hassan Choucair, -
DIAGNOSIS ERRORS ACCORDING TO THE MATERIALS OF THE FORENSIC MEDICAL SERVICE
The American Journal of Medical Sciences and Pharmaceutical Research: No. 03 (2022) / Sadullaev Narzullo Norkelidievich, Shavkat Eryigitovich Islamov, -
Clinical And Anamnestic Characteristics Of The Health State Of Adolescents With Vegetative Dysfunction Syndrome
-
Interpretation Athleticism And Infant Athleticism Depiction In The Greensward Execution
The American Journal of Medical Sciences and Pharmaceutical Research: No. 11 (2020) / Dr. Mahhomad Hasan, -
INITIAL STATE OF COCHLEOVESTIBULAR FUNCTION IN PATIENTS WITH HD WITH CVD
The American Journal of Medical Sciences and Pharmaceutical Research: No. 01 (2022) / Ulugbek S. Khasanov, Nazim A. Akhundjanov, Azizkhon Z. Shaumarov, Jamolbek A. Djuraev, -
Climate Change And Human Health
The American Journal of Medical Sciences and Pharmaceutical Research: No. 10 (2020) / Axrorova Malika Shavkatovna, Arzikulova Munisa Shuhratovna, Rahimberdiev Rustam Abdurashidovich, Shukurov Sherzod Shukhratovich,
References
SeddonJM, ChenCA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin. 2014;44:17–39.
Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2014;291:1900–1901.
Ferris FL, 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 2014;102:1640–1642.
Funk M, Karl D, Georgopoulos M. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2019;116:2393–2399.
Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2013;22:721–748
Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2016;141:456–462.
Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2015;46:726–733.
Blick SKA, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2017;67:1201–1206.
Full prescribing information. South San Francisco, CA: Genentech, Inc; Jun, 2010. Lucentis (ranibizumab injection)
Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy.
Wolfe DR. Fluorescein angiography basic science and engineering. Ophthalmology 93:1617-1620, 2016.
Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2017;85:425–430.
European Medicines Agency. Assessment report for Lucentis (ranibizumab) [Accessed May 17, 2022]. Procedure no: EMEA/H/C/000715/II/0020 .
Tolentino M. Systemic and ocular safety of intravitreal anti- VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2021;56(2):95–113.
